Diet is a modifiable risk factor for disease course and data over the past decade have emerged to indicate its role in Crohn’s disease (CD) and ulcerative colitis (UC). However, literature is riddled with misinterpretation of data, often leading to unexpected or conflicting results. The key understanding is that causative factors in disease development do not always proceed to an opportunity to change disease course, once established. Here, we discuss the data on dietary influences in three distinct disease states for CD and UC—predisease, active disease and quiescent disease. We appraise the literature for how our dietary recommendations should be shaped to prevent disease development and if or how that differs for CD and UC induction therapy and maintenance therapy. In UC, principles of healthy eating are likely to play a role in all states of disease. Conversely, data linking dietary factors to CD prevention and treatment are paradoxical with the highest quality evidence for CD treatment being exclusive enteral nutrition, a lactose, gluten and fibre-free diet comprising solely of ultraprocessed food—all dietary factors that are not associated or inversely associated with CD prevention. High-quality evidence from dietary trials is much awaited to expand our understanding and ultimately lead our dietary recommendations for targeted patient populations.
22 April 2020 in European Journal of Clinical Nutrition
Background and Aim: The role of dietitians in inflammatory bowel disease (IBD) care is evolving as evidence increasingly points to the role of diet in disease risk, pathogenesis and therapeutic outcomes. This narrative review by the ECCO committee of Dietitians (D‐ECCO) outlines the progression of dietetic care in IBD from supportive nutrition to a key component of therapeutic management. Methods: Literature related to the development of dietetic roles in IBD, the evolution of dietary guidelines and evidence, was reviewed by the D‐ECCO Committee working group. Results: Dietitians were once limited to supportive roles, now vital members of multidisciplinary IBD care team. Research has established diet as a modifiable environmental factor affecting intestinal inflammation via proposed mechanisms including microbiota, metabolite production and gut barrier integrity. Interventional studies support dietary strategies such as exclusive enteral nutrition and the Crohn's disease exclusion diet. The 2025 ECCO Consensus on Dietary Management of IBD redefines nutrition care as central to IBD management, outlining five pillars where dietitians with expertise in IBD should engage: induction and maintenance of remission, comorbidity management, nutritional assessment and optimisation and prevention. Conclusion: The evolution of dietetic care highlights the critical role of dietitians in IBD management. All patients should have access to dietitians with IBD expertise to ensure effective, personalised care. However, access is hindered by workforce shortages, lack of defined scope, standardised training and systemic barriers. To address this, the D‐ECCO Committee proposes a six‐step roadmap to defined and formalise the IBD dietitian role. International collaboration and real‐world data will be essential to fully integrate nutrition into evidence‐based IBD care.
Background: Growth impairment and poor nutritional status are recognized complications of pediatric inflammatory bowel disease (IBD), yet data specific to ulcerative colitis (UC) are limited. This systematic review aims to provide an overview of current knowledge on growth, nutritional status, and body composition in children and adolescents with UC. Methods: A systematic literature search was performed up to August 2025. Studies including patients aged 5–22 years with confirmed UC were reviewed. Results related to growth, nutritional status, and body composition were narratively synthesized to summarize findings. Results: Fifteen studies with 1575 patients with UC met inclusion criteria, comprising 5 prospective, 5 cross-sectional, and 5 retrospective designs. Although the included studies were conducted in broader IBD cohorts, only UC-specific outcomes were reported. The data were limited by sample size, heterogeneity in patient characteristics, outcome definitions, and assessment methods. The majority of patients had prolonged disease with remission or mild activity. Growth failure prevalence ranged from 7% to 36%, with weight deficits being more common than height deficits. Undernutrition affected up to 25% of patients, with variability across studies. Overweight and obesity were also observed, though most studies showed no significant differences between UC patients and controls. Only five very small studies assessed body composition, reporting inconsistent findings regarding reductions in lean body mass. Conclusions: Growth impairment and poor nutritional status can occur in children and adolescents with UC. Larger, standardized, high-quality studies focused specifically on UC are needed to better characterize its impact on growth and nutritional status, including the essential integration of body composition assessment.